Skip to main content

Table 1 Baseline characteristics of demographics, clinical and laboratory findings in Survivor group and Non-Survivor group

From: Risk factors for mortality in critically ill patients with COVID-19: a multicenter retrospective case-control study

  Total (N = 325) Survivor (N = 270) Non-Survivor (N = 55) P value
Demographics,clinical characteristics
 Age, years 58.0 (46.0–69.0) 56.0 (42.0–65.0) 70.0 (62.0–82.0) < 0.00
 Sex N (%)     1
  Male 189 (58%) 154 (57%) 35 (64%) 0.366
  Female 136 (42%) 116 (43%) 20 (37%)  
Comorbidity N(%) 155 (48%) 117 (43%) 38 (69%) 0.001
Hypertension 98 (30%) 71 (26%) 27 (49%) 0.001
Coronary heart disease 31 (10%) 20 (7%) 11 (20%) 0.004
Chronic kidney disease 5 (2%) 2 (1%) 3 (6%) 0.036
Diabetes 38 (12%) 26 (10%) 12 (22%) 0.010
Chronic obstructive lung 10 (3%) 6 (2%) 4 (7%) 0.070
Stroke 16 (5%) 7 (3%) 9 (16%) < 0.001
Carcinoma 10 (3%) 8 (3%) 2 (4%) 0.679
Other 61 (19%) 45 (17%) 16 (29%) 0.030
Temperature(°C),median(IQR) 37.0 (36.5–37.8) 37.0 (36.6,37.9) 36.6 (36.3–37.4) 0.014
Pulse(beats per min), median(IQR) 88 (80.0–97.0) 87.0 (80.0,96.0) 90.0 (80.3–99.5) 0.356
Respiratory rate(breaths per min), median(IQR) 20.0 (20.0–23.0) 20.0 (19.0,22.0) 23.0 (20.0–26.0) < 0.001
Systolic blood pressure, median(IQR) 127.0 (117.0–138.0) 125.0 (115.0,138.0) 130.5 (127.3–146.5) 0.003
Diastolic blood pressure, median(IQR) 78.0 (70.0–85.0) 78.0 (70.0,85.0) 76.0 (65.8–85.0) 0.222
APACH II sore, median(IQR) 6.0 (4.0–9.0) 5.0 (3.0–7.0) 13.0 (9.0–29.0) < 0.001
SOFA sore, median(IQR) 2.0 (2.0–4.0) 2.0 (1.0,3.0) 7.0 (4.0–14.0) < 0.001
Clinical Classifications N (%)     < 0.001
 Severe type 222 (68%) 216 (80%) 6 (11%)  
 Critical type 103 (32%) 54 (20%) 49 (89%)  
 In-hospital days 20.0 (14.0–28.0) 20.0 (14.0–28.0) 15.0 (7.0–28.0) 0.003
Total course of disease a 28.0 (19.0–37.0) 27.0 (19.0–36.0) 30.0 (20.0–38.0) 0.345
Laboratory findings, median(IQR)
 WBC, (1 × 109/L) 5.8 (4.2–8.3) 5.3 (4.1–7.1) 9.2 (5.6–15.7) < 0.001
 NEU,(1 × 109/L) 3.9 (2.6–6.5) 3.6 (2.4–5.4) 8.1 (4.8–14.4) < 0.001
 LYM,(1 × 109/L) 1.0 (0.6–1.4) 1.0 (0.7–1.5) 0.6 (0.4–0.8) < 0.001
 MON,(1 × 109/L) 0.4 (0.3–0.6) 0.4 (0.3–0.6) 0.4 (0.2–0.6) 0.205
 PLT,(1 × 109/L) 178.0 (144.0–233.5) 186.0 (147.5–239.5) 153.0 (84.5–199.5) < 0.001
 HGB,(g/L) 129.0 (117.0–141.0) 130.0 (119.5–142.5) 117.0 (94.0–133.5) < 0.001
 FIB,(g/L) 4.1 (3.4–4.8) 4.1 (3.4–4.8) 3.9 (3.0–4.6) 0.340
 IL-6,(pg/ml) 19.1 (7.7–42.8) 16.0 (7.1–33.8) 66.9 (22.6–112.5) < 0.001
 PCT,(ng/ml) 0.1 (0–0.2) 0.1 (0–0.1) 0.2 (0.1–0.4) < 0.001
 CRP,(mg/L) 25.2 (8.7–63.6) 20.1 (7.9–46.3) 70.0 (34.9–150.5) < 0.001
 ALT, (U/L) 24.0 (16.1–37.9) 24.0 (16.0–37.4) 25.8 (18.0–43.8) 0.378
 TBIL, (umol/L) 11.3 (7.9–15.6) 10.9 (7.5–15.0) 13.3 (10.2–20.1) 0.004
 DBIL, (umol/L) 3.7 (2.4–6.1) 3.5 (2.2–5.2) 5.8 (3.6–8.6) < 0.001
 CREA, (μmol/L) 65.0 (52.5–80.9) 64.0 (52.0–80.0) 68.4 (55.3–104.8) 0.096
 Lac, (mmol/L) 1.6 (1.2–2.2) 1.5 (1.1–2.1) 1.9 (1.3–2.5) 0.077
 Pa02/FiO2 237.9 (164.2–285.0) 247.3 (196.6–286.5) 143.3 (90.2–235.6) < 0.001
  1. a Total course of disease:Time from illness onset to death or discharge, days; IQR Inter-Quartile Range, APACHE II Acute Physiology and Chronic Health Evaluation II score, SOFA Sequential Organ Failure Assessment, WBC White blood cell count, NEU Neutrophil, LYM Lymphocyte count, MON Monocytes, PLT Platelet count, HGB Hemoglobin, FIB Fibrinogen, IL-6 Interleutin-6, PCT Procalcitonin, CRP C-reactive protein, ALT Alanine aminotransferase, TBIL Total bilirubin, DBIL Direct bilirubin, CREA Creatine, Lac lactic acid